What Akynzeo Treats: Main Uses and Benefits

Akynzeo is commonly used to help manage symptoms related to physical discomfort and nausea in adults undergoing certain cancer treatments. Its therapeutic scope is applied across domains where additional symptomatic support is needed in oncology supportive care.

---

The medication is commonly used to help with prevention in conditions characterized by periods of heightened symptoms associated with chemotherapy regimens classified as having a high (HEC) or moderate (MEC) risk. This focus addresses symptom clusters that may become intense or disruptive across both the immediate sickness (acute phase, within 24 hours) and the subsequent symptoms that can manifest days later (delayed phase). By providing this support, Akynzeo helps ease the overall symptom burden and assists with maintaining functional stability when symptoms interfere with daily comfort.

Supportive Focus: Symptom Management in CINV
Therapeutic Area: Used for managing symptoms related to Chemotherapy-Induced Nausea and Vomiting (CINV).
Symptom Domains: Acute emesis, delayed emesis, and generalized sickness.
Patient Benefit: Supports general well-being during symptomatic phases.

Regulatory References

1. European Medicines Agency therapeutic overview

Eligibility Map: Who can and cannot use Akynzeo — Official Regulatory Information

The following information summarizes the population eligibility and non-eligibility rules for Akynzeo as explicitly defined in government-approved regulatory documents.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults are the indicated patient population for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.
Populations for whom use is not recommended	Use should be avoided in patients with severe renal impairment or end-stage renal disease. Use should also be avoided in patients with severe hepatic impairment (Child-Pugh score ge 9).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substances, netupitant or palonosetron, or to any excipients. Use is contraindicated during pregnancy, and women of childbearing potential must use effective contraception.
Age-related eligibility rules	Safety and effectiveness have not been established in the pediatric population (children under 18 years of age). Caution should be exercised in patients over 75 years of age due to limited clinical experience.
Pregnancy and lactation eligibility status	Contraindicated during pregnancy; breastfeeding must be discontinued during treatment.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Akynzeo by setting clear exclusionary criteria for adults as the target population. Absolute prohibitions, or contraindications, are set for patients with documented hypersensitivity and for women who are pregnant. Furthermore, use is avoided in patients with severe reductions in hepatic or renal function due to lack of established safety or increased exposure risk.

Interactions with other medicines and products

Akynzeo's interaction profile is primarily determined by its netupitant component, which is classified as a moderate inhibitor of the CYP3A4 enzyme (a pharmacokinetic interaction) and a substrate for CYP3A4. The palonosetron component contributes to pharmacodynamic risks.

Category	Interaction Restriction or Outcome
Contraindicated Combinations	Co-administration is formally contraindicated with certain drugs, including Pimozide, Terfenadine, Astemizole, and Cisapride, due to the potential for seriously elevated plasma concentrations of these medicines.
Strong CYP3A4 Inducers	The co-administration of strong CYP3A4 Inducers (e.g., Rifampicin) is generally avoided as it substantially decreases netupitant plasma concentration, potentially reducing the antiemetic's efficacy.
CYP3A4 Substrates	Netupitant increases the plasma concentration (exposure) of co-administered medicines metabolized by CYP3A4. This requires a mandatory dose reduction for Dexamethasone when co-administered with Akynzeo.
Serotonergic Drugs	Concomitant use with other Serotonergic Drugs (e.g., SSRIs, SNRIs) has been associated with a documented risk of serotonin syndrome (a pharmacodynamic interaction).
Population Note	Avoid use in patients with severe hepatic impairment due to a documented increase in systemic exposure to netupitant.

The oral capsule may be administered with or without food. Additionally, netupitant is a weak inhibitor of P-glycoprotein (P-gp), an interaction that may affect the plasma levels of co-administered P-gp substrates.

The mechanism of Akynzeo involves dual antagonism, synchronously blocking the activity of two distinct neurotransmitter pathways: the Serotonin-3 ( 5-HT3) receptor and the Neurokinin-1 ( NK1) receptor. Palonosetron acts on the 5-HT3 receptor, which inhibits the transmission of rapid, acute signals from the gut's vagal nerve endings to the brainstem. Netupitant blocks the NK1 receptor, which primarily reduces the central signal processing activity mediated by the neuropeptide Substance P.

A critical mechanistic feature is the duration of the receptor blockade. Netupitant is characterized by its prolonged, high-affinity occupancy of the central NK1 receptor, which results in the binding site remaining deactivated for a sustained period. This long-lasting modulation of the Substance P pathway alters the physiological signaling pattern and duration of signal transmission associated with the delayed phase.

The combination exhibits mechanistic synergy by targeting signals in different anatomical locations and temporal phases (acute and delayed). This co-action supports a coordinated interruption of signaling across the relevant pathways, leading to the reduction of Medullary Vomiting Center excitability and modulation of the neurological function required to execute the emetic reflex.

The use of Akynzeo is governed by specific administration protocols that define the standardized approach for each chemotherapy cycle, available in two forms. The medicine can be administered orally as a hard capsule (netupitant 300 mg/palonosetron 0.5 mg) or intravenously as a solution for injection (fosnetupitant 235 mg/palonosetron 0.25 mg).

Regardless of the route, the regimen is a single fixed dose given only once per cycle, administered prior to the start of the cytotoxic treatment. The administration is coupled with the use of a reduced dose of Dexamethasone.

For oral administration, one capsule is taken approximately one hour prior to the chemotherapy. The hard capsule must be swallowed whole, as it contains four components, and it may be taken with or without food.

Alternatively, the intravenous (IV) route involves infusing the fixed single dose over 30 minutes, beginning roughly 30 minutes before the chemotherapy starts. The lyophilized IV form requires mandatory reconstitution and dilution in 5% Dextrose or 0.9% Sodium Chloride solutions prior to this 30-minute infusion.

Guidance specifies that the medicine should be avoided in adults with severe hepatic impairment (Child-Pugh ge 9) or severe renal impairment (CrCl < 30 mL/min or end-stage renal disease), as the proper dosing has not been established in these populations. Furthermore, the safety and effectiveness of Akynzeo have not been established in patients under the age of 18.

Overview of Clinical Evidence

Akynzeo (netupitant/palonosetron) is a fixed-dose combination therapy indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). The clinical program established its use in combination with dexamethasone for chemotherapy regimens categorized as highly emetogenic (HEC) and moderately emetogenic (MEC).

Key studies evaluated the drug's effectiveness against standard antiemetic regimens, often focusing on the Complete Response (CR) endpoint, defined as no vomiting and no use of rescue medication.

---

Efficacy Findings

Clinical trials have generally reported improved control over CINV, particularly during the delayed phase (24 to 120 hours after chemotherapy), when compared to palonosetron alone. The combination addresses both the acute (Serotonin, 5-HT3) and delayed (Neurokinin-1, NK-1) pathways involved in CINV, allowing for a single-dose administration per chemotherapy cycle.

Chemotherapy Emetogenicity	Key Finding (Comparison)	Complete Response Rate (Overall Phase)
Highly Emetogenic (HEC)	Associated with superior CR vs. palonosetron alone	Approximately 74% vs. 67%
Moderately Emetogenic (MEC)	Demonstrated high and maintained CR rates across multiple cycles	Consistent rates observed in multi-cycle trials

Further research, including Phase IV trials, has examined the combination's use in patients receiving MEC who have additional risk factors for CINV, reporting statistically significant improvements in CR when compared to standard two-drug prophylaxis.

---

Extended Phase Control

Recent data also investigated the combination's effects beyond the typical 5-day assessment window, reporting high CR rates maintained into the extended phase (up to 120–168 hours post-chemotherapy). This sustained activity is attributed to the long half-lives of both netupitant and palonosetron. The safety profile across multiple cycles of chemotherapy has been reported as generally consistent with that observed in single-cycle studies.

Common questions about Akynzeo (FAQ)

Q: What is Akynzeo used for?

A: Akynzeo (netupitant and palonosetron) is an approved combination medication used to help prevent nausea and vomiting that may occur immediately and up to several days after receiving certain types of chemotherapy (a treatment known as CINV, or chemotherapy-induced nausea and vomiting).

---

Q: How is Akynzeo administered?

A: Akynzeo is typically given as a single-dose regimen about one hour before the start of a chemotherapy session. It may be administered by a healthcare professional as an oral capsule or as an intravenous (IV) infusion.

---

Q: How does Akynzeo work?

A: Akynzeo is a combination of two medicines. Netupitant helps block a specific substance in the body (called Substance P) that signals nausea. Palonosetron helps block a different substance (called serotonin) that also contributes to triggering vomiting. By targeting these two separate pathways, the combination helps to address both immediate and delayed nausea and vomiting associated with chemotherapy.

---

Q: Is Akynzeo safe to take with other medications?

A: Before starting Akynzeo, it is important to discuss all current medications, including prescription, over-the-counter drugs, and herbal supplements, with a healthcare provider. Drugs that affect the liver's ability to process medications, particularly CYP3A4 inhibitors and inducers, may interact with netupitant, one of the components of Akynzeo. The healthcare provider will assess potential interactions based on the patient's full medication list.

---

Q: What are the common side effects of Akynzeo?

A: The most frequently reported adverse effects observed in clinical trials included headache, constipation, and fatigue. Other reported effects included indigestion and dizziness. It is important to remember that not everyone experiences side effects, and they are usually mild. If a person experiences a severe or persistent side effect, they should contact their healthcare provider immediately.

---

Q: Are there any warnings or precautions for taking Akynzeo?

A: A healthcare provider should be informed if a patient has a history of heart problems, such as a prolonged QT interval or other heart rhythm abnormalities. Akynzeo contains palonosetron, which has been associated with changes in heart rhythm in some cases. Individuals with a history of severe constipation should also discuss this with their doctor, as the drug can potentially worsen this condition.

---

Q: Is there a generic version of Akynzeo available?

A: Akynzeo is a brand-name combination product. The components, netupitant and palonosetron, may be available separately, but they are generally formulated together in this specific product. Patients should consult their pharmacist or insurance provider regarding the availability of generic alternatives or specific drug combinations.

Storage and Disposal Requirements for Akynzeo

Official regulatory documents detail specific storage and disposal requirements for both Akynzeo formulations.

Akynzeo Capsules (Netupitant/Palonosetron)

The capsules must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The container must be kept tightly closed and stored away from light, excess heat, and moisture. All capsules must be kept out of the reach of children.

Akynzeo Injection (Fosnetupitant/Palonosetron)

Unopened vials are stored at room temperature, 20 C to 25 C. The final diluted solution must not exceed 24 hours from reconstitution to the start of infusion. The injection is for single use only, and any unused portion remaining in the vial or bag must be discarded.

Disposal Instructions

Expired or unused medication, including any remnants of the injection solution, must be disposed of in accordance with local regulations for pharmaceutical waste.